Pre-made Abciximab benchmark antibody (Fab Fusion, anti-ITGA2B;ITGB3 therapeutic antibody, Anti-BDPLT16/BDPLT2/CD41/CD41B/GP2B/GPIIb/GT/GT1/GTA/HPA3/PPP1R93;BDPLT16/BDPLT2/BDPLT24/CD61/GP3A/GPIIIa/GT/GT2 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-made Abciximab benchmark antibody (Fab Fusion, anti-ITGA2B;ITGB3 therapeutic antibody, Anti-BDPLT16/BDPLT2/CD41/CD41B/GP2B/GPIIb/GT/GT1/GTA/HPA3/PPP1R93;BDPLT16/BDPLT2/BDPLT24/CD61/GP3A/GPIIIa/GT/GT2 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Abciximab, a glycoprotein IIb/IIIa receptor antagonist manufactured by Janssen Biologics BV and distributed by Eli Lilly under the trade name ReoPro, is a platelet aggregation inhibitor mainly used during and after coronary artery procedures like angioplasty to prevent platelets from sticking together and causing thrombus (blood clot) formation within the coronary artery. It is a glycoprotein IIb/IIIa inhibitor.[3]
| Products Name (INN Index) | Pre-Made Abciximab Biosimilar, Fab Fusion, Anti-Itga2B/Itgb3 Antibody: Anti-BDPLT16/BDPLT2/CD41/CD41B/GP2B/GPIIb/GT/GT1/GTA/HPA3/PPP1R93;BDPLT16/BDPLT2/BDPLT24/CD61/GP3A/GPIIIa/GT/GT2 therapeutic ant |
|---|---|
| INN Name | abciximab |
| Target | ITGA2B/ITGB3 |
| Format | Fab Fusion |
| Derivation | Chimeric |
| Species Reactivity | Human |
| CH1 Isotype | Fab – G1 – kappa |
| VD LC | Fab – G1 – kappa |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | Centocor?Inc. (Horsham PA USA) / Eli?Lilly (Indianapolis IN USA) / Janssen Biotech,?Inc (Horsham PA USA) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | ITGA2B/ITGB3 |
| Package |
